unlimited free of charge for lung cancer treatment for Yuhan Corporation

(1)Yuhan Corporation Lekraza Unlimited
(2)Free supply…the only spirit
(3)Reporter Lee Choon-hee
(4)Input 202307101702
(5)ⓒ Time to read 2 minutes and 19 seconds
(6)First-line treatment for non-small cell lung cancer. Right
(7)Introducing Sympathetic Usage Program EAP
(8)Foreign patients also receive benefits when prescribing in Korea only after patient consent, doctor evaluation, and IRB approval
(9)Yuhan Corporation’s third-generation non-small cell lung cancer treatment, Rekrajasung Clear LaserTinib, will be supplied free of charge to domestic patients

(1)On the afternoon of the 10th, Yuhan Corporation is the Plaza Lake in Jung-gu, Seoul
(2)At a meeting of RD and social contribution reporters at Yuhan Corporation held at Tel, the company unveiled its plan to implement the EAP Early Access Program, a sympathetic use program that provides Recraza to Korean patients free of charge, in response to the approval of Recraza’s first treatment for non-small cell lung cancer. Currently, consultations are underway with each medical institution that wishes to proceed with EAP, and the first beneficiary patient is expected to be provided within this month. If eligible for EAP, patients will receive free of charge of Recraza, which is the annual price of 75.5 million won based on the current second-line treatment insurance drug price